184 related articles for article (PubMed ID: 35187488)
21. NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.
Toonen JA; Anastasaki C; Smithson LJ; Gianino SM; Li K; Kesterson RA; Gutmann DH
Hum Mol Genet; 2016 May; 25(9):1703-13. PubMed ID: 26908603
[TBL] [Abstract][Full Text] [Related]
22. Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth.
Daginakatte GC; Gutmann DH
Hum Mol Genet; 2007 May; 16(9):1098-112. PubMed ID: 17400655
[TBL] [Abstract][Full Text] [Related]
23. Temporal, spatial, and genetic constraints contribute to the patterning and penetrance of murine neurofibromatosis-1 optic glioma.
Brossier NM; Thondapu S; Cobb OM; Dahiya S; Gutmann DH
Neuro Oncol; 2021 Apr; 23(4):625-637. PubMed ID: 33080011
[TBL] [Abstract][Full Text] [Related]
24. The Sociobiology of Brain Tumors.
Gutmann DH
Adv Exp Med Biol; 2020; 1225():115-125. PubMed ID: 32030651
[TBL] [Abstract][Full Text] [Related]
25. Leveraging murine models of the neurofibromatosis type 1 cancer predisposition syndrome to elucidate the cellular circuits that drive pediatric low-grade glioma formation and progression.
Gutmann DH
Neurooncol Adv; 2024; 6(1):vdae054. PubMed ID: 38855054
[TBL] [Abstract][Full Text] [Related]
26. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
[TBL] [Abstract][Full Text] [Related]
27. Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma.
Dasgupta B; Yi Y; Hegedus B; Weber JD; Gutmann DH
Cancer Res; 2005 Nov; 65(21):9843-50. PubMed ID: 16267007
[TBL] [Abstract][Full Text] [Related]
28. Natural history of neurofibromatosis 1-associated optic nerve glioma in mice.
Bajenaru ML; Garbow JR; Perry A; Hernandez MR; Gutmann DH
Ann Neurol; 2005 Jan; 57(1):119-27. PubMed ID: 15622533
[TBL] [Abstract][Full Text] [Related]
29. Treatment during a developmental window prevents NF1-associated optic pathway gliomas by targeting Erk-dependent migrating glial progenitors.
Jecrois ES; Zheng W; Bornhorst M; Li Y; Treisman DM; Muguyo D; Huynh S; Andrew SF; Wang Y; Jiang J; Pierce BR; Mao H; Krause MK; Friend A; Nadal-Nicolas F; Stasheff SF; Li W; Zong H; Packer RJ; Zhu Y
Dev Cell; 2021 Oct; 56(20):2871-2885.e6. PubMed ID: 34428430
[TBL] [Abstract][Full Text] [Related]
30. Optic Pathway Gliomas in Neurofibromatosis Type 1.
Campen CJ; Gutmann DH
J Child Neurol; 2018 Jan; 33(1):73-81. PubMed ID: 29246098
[TBL] [Abstract][Full Text] [Related]
31. C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.
Singh D; Dromel PC; Perepelkina T; Baranov P; Young M
Cell Transplant; 2020; 29():963689720964383. PubMed ID: 33356508
[TBL] [Abstract][Full Text] [Related]
32. Brain tumors in Neurofibromatosis type 1.
Costa AA; Gutmann DH
Neurooncol Adv; 2019; 1(1):vdz040. PubMed ID: 32642668
[TBL] [Abstract][Full Text] [Related]
33. Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1.
Warrington NM; Woerner BM; Daginakatte GC; Dasgupta B; Perry A; Gutmann DH; Rubin JB
Cancer Res; 2007 Sep; 67(18):8588-95. PubMed ID: 17875698
[TBL] [Abstract][Full Text] [Related]
34. The impact of coexisting genetic mutations on murine optic glioma biology.
Kaul A; Toonen JA; Gianino SM; Gutmann DH
Neuro Oncol; 2015 May; 17(5):670-7. PubMed ID: 25246427
[TBL] [Abstract][Full Text] [Related]
35. Brain gliomas, hydrocephalus and idiopathic aqueduct stenosis in children with neurofibromatosis type 1.
Glombova M; Petrak B; Lisy J; Zamecnik J; Sumerauer D; Liby P
Brain Dev; 2019 Sep; 41(8):678-690. PubMed ID: 31000370
[TBL] [Abstract][Full Text] [Related]
36. Neurofibromatosis type 1 and optic pathway glioma: Molecular interplay and therapeutic insights.
Khatua S; Gutmann DH; Packer RJ
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29049847
[TBL] [Abstract][Full Text] [Related]
37. NF1-like optic pathway gliomas in children: clinical and molecular characterization of this specific presentation.
Lobón-Iglesias MJ; Laurendeau I; Guerrini-Rousseau L; Tauziède-Espariat A; Briand-Suleau A; Varlet P; Vidaud D; Vidaud M; Brugieres L; Grill J; Pasmant E
Neurooncol Adv; 2020 Jul; 2(Suppl 1):i98-i106. PubMed ID: 32642735
[TBL] [Abstract][Full Text] [Related]
38. Single-cell RNA sequencing reveals immunosuppressive myeloid cell diversity during malignant progression in a murine model of glioma.
Rajendran S; Hu Y; Canella A; Peterson C; Gross A; Cam M; Nazzaro M; Haffey A; Serin-Harmanci A; Distefano R; Nigita G; Wang W; Kreatsoulas D; Li Z; Sepeda JA; Sas A; Hester ME; Miller KE; Elemento O; Roberts RD; Holland EC; Rao G; Mardis ER; Rajappa P
Cell Rep; 2023 Mar; 42(3):112197. PubMed ID: 36871221
[TBL] [Abstract][Full Text] [Related]
39. Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction.
Toonen JA; Ma Y; Gutmann DH
Neuro Oncol; 2017 Jun; 19(6):808-819. PubMed ID: 28039362
[TBL] [Abstract][Full Text] [Related]
40. Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation.
Pong WW; Higer SB; Gianino SM; Emnett RJ; Gutmann DH
Ann Neurol; 2013 Feb; 73(2):303-8. PubMed ID: 23424002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
